Igor Klepikov*

Pediatric Surgeon, Department of Pediatric Surgery, USA

*Corresponding Author: Igor Klepikov, Pediatric Surgeon, Department of Pediatric Surgery, USA.

Received: June 21, 2021; Published: September 18, 2021

The SARS-CoV-2 pandemic, despite the severity and tragedy of its manifestations, plays, oddly enough, a positive role for modern medicine. Some aspects of medical care have long required radical revision, and with the activation of the coronavirus, the need for new approaches and solutions has become more obvious, although old treatment stereotypes continue to determine the search strategy. Therefore, it is necessary to note the new facts and circumstances that have accumulated during the current pandemic, as well as to assess them impartially and properly in order to make the necessary adjustments.

References

1. Caramaschi S., et al. “Histopathological findings and clinicopathologic correlation in COVID-19: a systematic review”. Modern Pathology (2021).
2. V E Schaye., et al. “Collaborating Across Private, Public, Community, and Federal Hospital Systems: Lessons Learned from the Covid-19 Pandemic Response in NYC”. NEJM Catalyst Innovations in Care Delivery6 (2020).
4. J P Metlay., et al. “Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America”. American Journal of Respiratory and Critical Care Medicine7 (2019): e45-e67.
5. Kamat IS., et al. “Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis”. Clinical Infectious Diseases3 (2020): 538-542.
6. Ruuskanen O., et al. “Viral pneumonia". Lancet 377 (9773): 1264-1275.
7. WHO Solidarity Trial Consortium. “Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results”. The New England Journal of Medicine 384 (2021): 497-511.
8. A Ceccato and A Torres. “Sepsis and community-acquired pneumonia”. Annals of Research Hospitals 2 (2018): 7.
9. Grasselli G., et al. “Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy”. JAMA (2020).
10. S Richardson., et al. “Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area”. JAMA (2020).
11. Attaway A H., et al. “Severe covid-19 pneumonia: pathogenesis and clinical management”. BMJ 372 (2021): n436.
12. Zhang J., et al. “The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future”. Life Science 257 (2020): 118142.
13. EJ Rubin., et al. “Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup”. The New England Journal of Medicine 384 (2021): 1564-1565.
14. Cytokine Storm-to the Editor. The New England Journal of Medicine 384 (2021): e59.
15. The REMAP-CAP Investigators. “Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19”. The New England Journal of Medicine 384 (2021): 1491-1502.
16. Christiansen CF., et al. “SARS-CoV-2 infection and adverse outcomes in users of ACE inhibitors and angiotensin-receptor blockers: a nationwide case-control and cohort analysis”. Thorax 76 (2021): 370-379.
17. Albashir AAD. “Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors and Coronavirus Disease 2019 (COVID-19)”. South Medical Journal1 (2021): 51-56.
18. H Clifford Lane and Anthony S Fauci. “Research in the Context of a Pandemic”. The New England Journal of Medicine 384 (2020): 755-757.
19. Abeldaño Zuñiga RA., et al. “Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis”. Therapeutic Advances in Respiratory Disease 15 (2021): 17534666211007214.
20. Zhou B., et al. “COVID‐19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations”. Journal of Medical Virology (2021): 1-11.
21. Z Wu., et al. “Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention”. JAMA 13 (2020): 1239-1242.
22. K T Kadakia., et al. “Leveraging Open Science to Accelerate Research”. The New England Journal of Medicine (2021).
23. Keeley AJ., et al. “Asymptomatic SARS-CoV-2 infection: the tip or the iceberg?”. Thorax 75 (2020): 621-622.
24. Ra SH., et al. “Upper respiratory viral load in asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2 infection”. Thorax 76 (2021): 61-63.
25. Klepikov I. “The Meaning of Pulmonary Reflexes in the Pathogenesis of Acute Pneumonia”. Internal Medicine 7 (2017): 232.
26. Schwiegk, H. “Der Lungenentlastungsreflex”. Pflügers Archiv: European Journal of Physiology 236 (1935): 206-219.
27. Thillai M., et al. “Functional respiratory imaging identifies redistribution of pulmonary blood flow in patients with COVID-19”. Thorax 76 (2021): 182-184.
28. Prescott HC and Girard TD. “Recovery From Severe COVID-19: Leveraging the Lessons of Survival From Sepsis”. JAMA8 (2020): 739-740.
29. Klepikov I. “Acute pneumonia. New doctrine and first treatment results”. Lambert Academic (2020).
30. Igor Klepikov. “How many Pneumonias exist in nature?” Generis Publishing (2021).

Citation

Citation: Igor Klepikov. “COVID-19 Pneumonia: Finding Clinical Solutions”.Acta Scientific Medical Sciences 5.10 (2021): 99-103.

Copyright

Copyright: © 2021 Igor Klepikov. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.